Activity and toxicity profiles of the combinations bendamustine- lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1191-1193

  Mele, Giuseppe ^a   Spina, Alessandro ^a   Guaragna, Gianluca ^a   Giannotta, Angela ^a   Melpignano, Angela ^a   Quarta, Gianni ^a  

^a Division of Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; PARAPROTEIN; PLATINUM; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CHLORMETHINE DERIVATIVE; PYRAZINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INDUCTION CHEMOTHERAPY; INSOMNIA; LEG EDEMA; LETTER; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATIONAL HEALTH ORGANIZATION; NEUROLOGIC DISEASE; NEUTROPENIA; NORMAL VALUE; OVERALL SURVIVAL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SEPTICEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84899716261     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.820289     Document Type: Letter

References (7)

1. Cavo M, Galli M, Pantani L et al. Bortezomib-Thalidomidedexamethasone incorporated into autotranplantation is associated with more favorable outcomes after relapse in comparison with thalidomide-dexamethasone plus autotranplantation in multiple myeloma. Blood 2012; 120(Suppl. 1): Abstract 4210.
2. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-A randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132: 205-212.
3. Lentzsch S, O ' Sullivan A, Kennedy R, et al. Combination of bendamustine, lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma is safe an highly effective:results of phase I/II open-label, dose escalation study. Blood 2011; 118(Suppl. 1): Abstract 304.
4. Ponisch W, Bourgeois M, Wang S-Y et al. Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myeloma. Blood 2007; 110(Suppl. 1): Abstract 2723.
5. Berdeja J G, Couriel D R, Murphy P, et a l. A phase II trial of combined bendamustine, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients who are not candidates for high-dose chemotherapy: Results of a planned interim safety analysis. Blood 2011; 118(Suppl. 1): Abstract 2943.
6. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005; 90: 1287-1288.
7. Cheson BD, Wendtner CM, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas and multiple myeloma: Treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010; 10: 21-27.